Citadel Advisors’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $15.9M | Sell |
|
|||||
|
2025
Q2 | $39.1M | Buy |
|
|||||
|
2025
Q1 | $10.1M | Sell |
|
|||||
|
2024
Q4 | $8.5M | Buy |
|
|||||
|
2024
Q3 | $3.66M | Buy |
|
|||||
|
2024
Q2 | $772K | Sell |
|
|||||
|
2024
Q1 | $1.15M | Buy |
|
|||||
|
2023
Q4 | $174K | Buy |
|
|||||
|
2023
Q3 | $43.6K | Sell |
|
|||||
|
2023
Q2 | $1.48M | Buy |
|
|||||
|
2023
Q1 | $291K | Buy |
|
|||||
|
2022
Q4 | $70.8K | Sell |
|
|||||
|
2022
Q3 | $515K | Sell |
|
|||||
|
2022
Q2 | $982K | Buy |
|
|||||
|
2022
Q1 | $685K | Buy |
|
|||||
|
2021
Q4 | $623K | Buy |
|
|||||
|
2021
Q3 | $743K | Buy |
|
|||||
|
2021
Q2 | $1.07M | Buy |
|
|||||
|
2021
Q1 | – | Sell |
|
|||||
|
2020
Q4 | $6.4M | Buy |
|